Evercore ISI initiated coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a research note released on Monday, Briefing.com Automated Import reports. The firm issued an outperform rating and a $35.00 price target on the stock.
AKRO has been the topic of a number of other research reports. Jefferies Financial Group set a $189.00 price target on shares of salesforce.com and gave the stock a buy rating in a research note on Monday. JPMorgan Chase & Co. reiterated a sell rating and issued a $18.00 price target on shares of ABB in a research note on Monday. Finally, Roth Capital reiterated a buy rating on shares of Coeur Mining in a research note on Monday.
Shares of Akero Therapeutics stock opened at $20.64 on Monday. Akero Therapeutics has a 1 year low of $16.06 and a 1 year high of $21.94.
About Akero Therapeutics
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
Featured Article: Are we seeing the beginning of a new bubble?
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.